Abstract
Therapeutic antibodies targeting ovarian cancer (OvCa)-enriched receptors have largely been disappointing due to limited tumor-specific antibody-dependent cellular cytotoxicity. Here we report a symbiotic approach that is highly selective and superior compared with investigational clinical antibodies. This bispecific-anchored cytotoxicity activator antibody is rationally designed to instigate “cis” and “trans” cytotoxicity by combining specificities against folate receptor alpha-1 (FOLR1) and death receptor 5 (DR5). Whereas the in vivo agonist DR5 signaling requires FcγRIIB interaction, the FOLR1 anchor functions as a primary clustering point to retain and maintain a high level of tumor-specific apoptosis. The presented proof of concept study strategically makes use of a tumor cell-enriched anchor receptor for agonist death receptor targeting to potentially generate a clinically viable strategy for OvCa. Shivange et al. design antibodies combining specificities against FOLR1 and DR5 that restrict DR5-mediated apoptotic activation toward FOLR1-expressing ovarian cancer cells while eliminating ADCC dependency to induce cell death. These antibodies outperformed reported clinically tested DR5 agonist antibodies.
Original language | English |
---|---|
Pages (from-to) | 331-345.e11 |
Journal | Cancer Cell |
Volume | 34 |
Issue number | 2 |
DOIs | |
State | Published - Aug 13 2018 |
Keywords
- TRAIL-R2
- antibody therapy
- cancer
- cancer signaling
- caspases
- cell signaling
- dual-specificity targeting
- folate receptor alpha-1
- ovarian cancer
- targeted therapies